Ionis Pharmaceuticals, Inc. Operating Lease, Expense
Ionis Pharmaceuticals, Inc. (IONS) reported Operating Lease, Expense of $26.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-02-26
- Ionis Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2019-12-31 was $900.00K, a 12.50% increase year-over-year.
- Ionis Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2019-09-30 was $800.00K, a 20.00% decline year-over-year.
- Ionis Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2019-06-30 was $1.00M, a 11.11% increase year-over-year.
- Ionis Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2019-03-31 was $900.00K.
- Ionis Pharmaceuticals, Inc. operating lease, expense for fiscal 2025 was $26.00M, a 12.07% increase from fiscal 2024.
- Ionis Pharmaceuticals, Inc. operating lease, expense for fiscal 2024 was $23.20M, a 0.43% increase from fiscal 2023.
- Ionis Pharmaceuticals, Inc. operating lease, expense for fiscal 2023 was $23.10M, a 178.31% increase from fiscal 2022.
- Ionis Pharmaceuticals, Inc. operating lease, expense for fiscal 2022 was $8.30M, a 144.12% increase from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $26.00M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $23.20M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $23.10M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $8.30M 10-K · filed 2025-02-19 | |||
| 2021-12-31 | $3.40M 10-K · filed 2024-02-21 | |||
| 2020-12-31 | $3.70M 10-K · filed 2023-02-22 | |||
| 2019-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $1.70M derived: sum of 2 quarters · filed 2022-02-25 | $2.70M derived: sum of 3 quarters · filed 2022-02-25 | $3.60M 10-K · filed 2022-02-25 |
| 2019-09-30 | $800.00K 10-Q · filed 2019-11-06 | $1.80M derived: sum of 2 quarters · filed 2019-11-06 | $2.70M 10-Q · filed 2019-11-06 | $3.50M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $1.00M 10-Q · filed 2019-08-08 | $1.90M 10-Q · filed 2019-08-08 | $2.70M derived: sum of 3 quarters · filed 2021-02-24 | $3.70M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $900.00K 10-Q · filed 2019-05-09 | $1.70M derived: sum of 2 quarters · filed 2021-02-24 | $2.70M derived: sum of 3 quarters · filed 2021-02-24 | $3.60M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $1.80M derived: sum of 2 quarters · filed 2021-02-24 | $2.70M derived: sum of 3 quarters · filed 2021-02-24 | $2.60M 10-K · filed 2021-02-24 |
| 2018-09-30 | $1.00M 10-Q · filed 2019-11-06 | $1.90M derived: sum of 2 quarters · filed 2019-11-06 | $1.80M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $900.00K 10-Q · filed 2019-08-08 | $900.00K 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $1.70M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |